TRB Chemedica Int. SA

The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.

TRB Chemedica S.A. reached agreement with River Plate Biotechnology, Inc. (a subsidiary of Lantibio, Inc.) and Alcon for a license to market, in the United States, a treatment for dry eye based on hyaluronic acid. The candidate product is currently in Phase III clinical studies.

Synovial Fluid Replacement after Arthroscopy

VISCOSEAL® is a viscoelastic solution containing hyaluronic acid. This solution has viscoelastic properties that are very close to those of normal synovial fluid.

VISCOSEAL® is indicated as a synovial fluid replacement after arthroscopy. In clinical trials, it has been shown to relieve post-arthroscopic symptoms such as pain, swelling and impaired joint mobility, and to promote joint recovery.

VISCOSEAL® is administered into the joint cavity at the end of the arthroscopic procedure.

VISCOSEAL® is designed to aid recovery after arthroscopy.

pdf Prescribing information
Doctor information
Distributors
Contacts